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2ABSTRACT
This article provides an overview of present knowledge regarding the relationship 
between the cholinergic system and sigma-1 receptors, and discusses potential 
applications of sigma-1 receptor agonists in the treatment of memory deficits and 
cognitive disorders. Sigma-1 receptors, initially considered as a subtype of the opioid 
family, are unique ligand-regulated molecular chaperones in the endoplasmatic 
reticulum playing a modulatory role in intracellular calcium signaling and in 
the activity of several neurotransmitter systems, particularly the cholinergic 
and glutamatergic pathways. Several central nervous system (CNS) drugs show 
high to moderate affinities for sigma-1 receptors, including acetylcholinesterase 
inhibitors (donepezil), antipsychotics (haloperidol, rimcazole), selective serotonin 
reuptake inhibitors (fluvoxamine, sertraline) and monoamine oxidase inhibitors 
(clorgyline). These compounds can influence cognitive functions both via 
their primary targets and by activating sigma-1 receptors in the CNS. Sigma-1 
agonists show powerful anti-amnesic and neuroprotective effects in a large 
variety of animal models of cognitive dysfunction involving, among others (i) 
pharmacologic target blockade (with muscarinic or NMDA receptor antagonists 
or p-chloroamphetamine); (ii) selective lesioning of cholinergic neurons; (iii) 
CNS administration of ß-amyloid peptides; (iv) aging-induced memory loss, both 
in normal and senescent-accelerated rodents; (v) neurodegeneration induced by 
toxic compounds (CO, trimethyltin, cocaine), and (vi) prenatal restraint stress. 
Keywords: Acetylcholine, cholinergic system, cognition, sigma-1 receptors, 
memory, anti-amnesic effects, sigma-1 agonists, neurodegenerative disease 
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INTRODUCTION
Cholinergic neurotransmission is a crucial process underlying memory 
and cognitive function. Cholinergic basal forebrain neurons in the nucleus 
basalis magnocellularis innervate the cerebral cortex, amygdaloid complex, 
or hippocampus and are essential for learning and memory formation (1), (2). 
Some cortical cholinergic activity is lost in normal aging. Patients suffering from 
AD or related dementias display a severe degeneration of cholinergic neurons 
and a corresponding loss of cortical cholinergic neurotransmission, which is 
one of the factors underlying their memory deficits (3), (4), (5). Administration 
of  an anticholinergic drug, such as the muscarinic antagonist scopolamine, to 
experimental animals or healthy volunteers results in striking impairments 
of memory function which resemble Alzheimer dementia (6). On the other 
hand, acetylcholinesterase (AChE) inhibitors such as tacrine, physostigmine, 
rivastigmine and galantamine which suppress breakdown of the neurotransmitter 
acetylcholine, can temporarily improve memory function in some demented 
patients and in animal models of amnesia (7).
The sigma-1 receptor, a unique orphan receptor, is strongly expressed in neurons 
and in glia (8), (9). Neurosteroids, i.e. steroid hormones which are synthesized 
within the brain itself (10), (11), (12), (13), and sphingolipids (14) interact with 
sigma-1 sites which are now considered as ligand-regulated molecular chaperones 
modulating the activity of voltage-regulated and ligand-gated ion channels (15), 
intracellular calcium signaling (16), and the release of various neurotransmitters 
including acetylcholine (17), (18), (19) and glutamate (20). Occupancy of sigma-1 
receptors by agonists causes translocation of the receptor protein from the 
endoplasmatic reticulum to the cell membrane where the receptor can regulate 
ion channels and neurotransmitter release (21), (22) (Figure 1). The sigma-1 
receptor is implicated in cellular differentiation (23), (24), neuroplasticity (25), 
(26), neuroprotection (27), (28), and cognitive functioning of the brain (29).
As both the cholinergic system and sigma-1 receptors are implied in cognition, we 
will in this article present an overview of current knowledge regarding the relationship 
between these neuronal pathways, and discuss potential applications of sigma-1 
receptor agonists in the treatment of memory deficits and cognitive disorders.
ACETYLCHOLINE AND SIGMA-1 RECEPTOR FUNCTION
Sigma-1 receptor agonists are potent modulators of acetylcholine release, both in 
vitro and in vivo. Igmesine and (+)SKF 10,047 potentiate the KCl-evoked release of 3H-acetylcholine from rat hippocampal slices, and this effect can be blocked 
by the sigma antagonist haloperidol (18). The sigma-1 receptor agonist SA4503 
dose-dependently increases the electrically evoked release of 3H-acetylcholine 
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Using in vivo microdialysis in freely moving rats, extracellular acetylcholine 
levels in the frontal cortex were found to be acutely and dose-dependently increased 
upon administration of the sigma-1 receptor agonists (+)-SKF 10,047, (+)-3-PPP, 
(±)-pentazocine and DTG. The effect of SKF 10,047 was stereoselective and it could 
be reversed by the sigma antagonist haloperidol (30), (31). In later experiments, 
(+)-SKF 10,047 was shown to also increase extracellular acetylcholine in the 
hippocampus in a stereoselective fashion and this effect could also be blocked by 
haloperidol (32). Regional differences in the stimulation of acetylcholine release by 
sigma-1 receptor agonists were subsequently observed. (+)-SKF 10,047 and DTG 
increased the release of acetylcholine in hippocampus and frontal cortex, but in 
the rat striatum, DTG had no and (+)-SKF 10,047 had only a marginal effect (33). 
Acetylcholine release in the hippocampus and frontal cortex was also strongly 
increased by the sigma-1 agonist SA4503, whereas acetylcholine release in the 
striatum was not affected (19), (34) (see Figure 2). The absence of an increase of 
striatal acetylcholine levels after administration of sigma-1 receptor agonists may 
Figure 2. Upper panel: The sigma-1 
receptor agonist SA4503 (10 mg/kg, 
per os, administered at time zero) 
increases extracellular acetylcholine 
levels in the frontal cortex but not in 
the striatum of freely moving rats. 
Lower panel: The effect of SA4503 on 
acetylcholine release is counteracted 
by the sigma-1 receptor antagonist 
NE-100 (0.5 mg/kg, co-administered 
with SA4503). After (19), (34).
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2be the reason why such drugs do not display some undesired side effects which are frequently seen after administration of acetylcholinesterase (AChE) inhibitors (19).Since selective sigma-1 receptor agonists can facilitate the activity of cholinergic systems by stimulating acetylcholine release, particularly in the cortex and hippocampus, such drugs have the potential to ameliorate the memory impairments resulting from cholinergic dysfunction.However, the capability of sigma-1 receptor agonists to ameliorate such impairments appears to be not solely due to modulation of residual acetylcholine release. In a recent study involving the potent and selective sigma-1 agonist (±)-PPCC (Ki at muscarinic receptors > 10,000 nM) and cholinergic lesions of varying severity, it was noted that the anti-amnesic effects of the sigma receptor agonist occur even in animals with complete cholinergic depletion, i.e. a total absence of cholinergic neurons in the basal forebrain nuclei (35). Pretreatment of animals with the sigma-1 receptor antagonist BD1047 blocked the anti-amnesic effects of (±)-PPCC (36). Thus, PPCC appears to improve cognition through sigma-1 receptors via additional, other mechanisms than stimulation of acetylcholine release. Some possible mechanisms are discussed in subsequent sections of this paper.
CHANGES OF SIGMA RECEPTOR DENSITY IN AGING 
AND NEURODEGENERATIVE DISEASEWhen sigma-1 receptor density in the brain of aged (20-28 years old) and young adult (4-8 years old) monkeys was compared using the radioligand 11C-SA4503 
and PET, a highly significant increase (160-210%) of the binding potential (BP) was observed in aged animals (37). In a similar PET study in humans, 11C-SA4503 binding was found to be unchanged in the human brain during healthy aging (38). This contrasts strikingly with the age-dependent loss of cholinergic, glutamatergic and dopaminergic receptors which occurs in primates (Figure 3). Using autoradiography and the non-subtype-selective sigma ligand 3H-DTG, 
a significant, 26% loss of binding sites was noted in the CA1 stratum pyramidale region of the hippocampus of Alzheimer’s disease (AD) patients as compared 
to healthy controls. This loss of sigma receptors correlated with a 29% loss of pyramidal cells (39). These preliminary results suggested that sigma receptors are preferentially located on pyramidal cells in the CA1 region of the hippocampus. In later PET studies, a loss of sigma-1 receptors from the brain of patients with AD was indeed observed (40). The BP of the sigma-1 ligand 11C-SA4503 was 
significantly reduced (by 44 to 60%) in the frontal, temporal, and occipital lobe, cerebellum and thalamus of early AD patients as compared to healthy controls, but not in the hippocampus (41). Two genetic variants of the sigma-1 receptor gene could affect the susceptibility of humans to AD, i.e. G-241T/C-240T (rs. 1799729) in the proximal promoter 
region and A61C (resulting in an amino acid substitution Q2P) in the first exon 
34
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(42). The haplotype TT-C has been suggested to provide protection against AD. 
However, in a later study in a group of Polish patients (219 subjects with late-onset 
AD, 97 subjects with mild cognitive impairment and 308 nondemented subjects), 
no significant differences for the sigma-1 receptor allele, genotype, haplotype, 
and diplotype distributions were observed between the studied groups (43). 
In a small group of patients with early Parkinson’s disease (n = 6), the BP of 
11C-SA4503 was found to be significantly lower on the more affected than the less 
affected side of the anterior putamen, although there was no significant difference in 
BP between patients and controls (44). These data suggest that Parkinson’s disease 
may be associated with a loss of sigma-1 receptors from the putamen, although the 
decrease is less striking than that observed in the cerebral cortex in AD.
In the rodent brain, sigma-1 receptor density was generally found to be preserved 
during aging. In a recent study involving healthy controls and senescent-accelerated 
mice (SAM), no differences between 6-, 9- and 12-month old rodents regarding 
the sigma-1 receptor density of various brain regions were observed, neither at 




Figure 3. Age-related increases of sigma-1 receptor density in rhesus monkey brain (upper left) 
compared to the decreases of muscarinic M1/M4, serotonin-2A (5-HT2A), and dopamine D2/D3 
receptor numbers with aging in human brain. Data from (195), (196), (197), and (198), respectively.
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210,047). However, in aged (12-mo) SAM, the antidepressant efficacy of the sigma-1 
agonist igmesine was increased. This augmented response may be due to decreased 
levels of neurosteroids in these animals, particularly progesterone, a steroid with 
sigma-1 receptor antagonist action (45). The efficacy of sigma-1 receptor agonists 
is known to be inversely correlated to brain progesterone levels. In rats treated with 
chronic intracerebroventricular infusion of beta-amyloid(1-40) protein, or in beta-
amyloid(25-35) peptide-treated mice, a significant decrease of cerebral progesterone 
levels is  accompanied by a corresponding increase of the antidepressant activity of 
sigma-1 receptor agonists (46), (47). In another study on murine ageing, no differences 
in cerebral sigma-1 receptor density were observed between 2-mo and 24-mo old 
C57/BL6 mice, neither at the mRNA nor at the protein level (48). 
Changes of sigma-1 and sigma-2 receptors in aging rat brain have been 
examined as well, by applying the radioligands 3H-SA4503, 3H-(+)pentazocine and 
3H-DTG for binding studies in brain homogenates of 1.5 mo, 6-, 12- and 24-mo old 
Fisher-344 rats. The number of binding sites increased with aging, but the binding 
affinity of all ligands was decreased. Apparently, increases of receptor density 
(over)compensate for a reduced affinity of the receptor proteins to agonists in 
this rodent strain, and as a consequence, ligand binding is increased at old age 
(49), particularly at ages greater than 12 months. In an older study which used 
3H-haloperidol (in combination with 50 nM unlabeled spiperone) to quantify 
sigma-1 plus sigma-2 receptors, receptor density in the brain of Fisher-344 rats 
was found to be unaltered between postnatal day 1 and age 12 months (50).
These findings of a preserved receptor density may perhaps not be generalized 
to all rat strains, since middle-aged Sprague-Dawley rats (5-6 mo old) were reported to have fewer sigma binding sites and sites with lower affinity for 
3H-DTG than young adult animals (2-3 mo old). The older animals also exhibited a 
decreased behavioral response to sigma ligands injected into the substantia nigra 
(51). Another research group which used 3H-(+)-PPP confirmed that the binding 
sites for this ligand in the brain of Sprague-Dawley rats are present at high density 
during the perinatal period, and decline thereafter (52).
SIGMA LIGANDS IMPROVE COGNITION IN ANIMAL 
MODELS OF COGNITIVE IMPAIRMENT
Sigma-1 agonists (applied systemically) have shown anti-amnesic efficacy in 
several animal models of cognitive impairment. Both pharmacological and 
pathological models of amnesia have been examined (see Table 1 for an overview). 
These include: (i) cholinergic deficits (either induced by muscarinic antagonists 
or by lesions of the forebrain or the nucleus basalis resulting in a selective loss 
of cholinergic neurons); (ii) pathology induced by direct administration of 
ß-amyloid(25-35) peptide to the rodent CNS, an animal model of Alzheimer’s 
36
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disease; (iii) aging-induced losses of memory function, both in normal mice 
and SAM; (iv) neurodegeneration caused by exposure of animals to CO gas, or 
to trimethyltin; (v) prenatal stress (restraint, or exposure to cocaine), and (vi) 
glutamatergic, serotonergic, or calcium channel deficits induced by various drugs 
The beneficial effects of sigma-1 receptor agonists on cognitive performance 
were detected in many different cognitive tests assessing short-term (working 
memory), long-term (reference memory), contextual or spatial memory processes.
For example, the sigma-1 receptor agonists (+)-SKF 10,047, pentazocine, DTG, 
(+)-3-PPP, igmesine and SA4503 prevented the scopolamine-induced amnesia 
of mice and rats in passive avoidance tasks, and the beneficial action of these 
compounds was blocked by sigma-1 receptor antagonists like NE-100. The 
anti-amnesic effects of SA4503 were blocked after sigma-1 receptor antisense 
administration, but not after administration of a mismatch oligodeoxynucleotide 
(34), (53), (54), (55), (56). Thus, activation of the sigma-1 receptor is involved in the 
improvement of cognition, and sigma-1 agonists have potential for the treatment 
of amnesia resulting from cholinergic dysfunction.
Sigma-1 receptor agonists such as (+)-SKF 10,047, (+)-pentazocine, DTG, 
PRE-084 and SA4503 also showed a potent anti-amnesic action against the 
cognitive deficits induced by NMDA-receptor blockade in mice and rats, e.g. 
treatment of animals with the non-competitive NMDA receptor antagonist 
dizocilpine before the learning test. These beneficial effects were stereoselective 
and were blocked by pretreatment of animals with sigma-1 antagonists such as 
BMY 14802, haloperidol or NE-100 (see Table 1 for references).
Neurotoxicity models of cognitive impairment which have been employed for 
testing cognitive enhancement by sigma-1 receptor agonists include repeated 
exposure of mice to CO gas and trimethyltin administration to rats. The former 
model results after 5 to 7 days in neuronal death that remains restricted to the CA1 
area of the hippocampus (57). Trimethyltin administration results in damage of 
selective neural populations from limbic structures of the brain (58), (59). In such 
neurotoxicity models, similar findings were obtained as in the pharmacological 
models of amnesia, i.e. sigma-1 receptor agonists improved cognitive performance 
and this improvement could be blocked by sigma-1 receptor antagonists. 
However, in contrast to the scopolamine or dizocilpine-induced amnesia, cognitive 
impairments after exposure of animals to CO or trimethyltin were alleviated not 
only by sigma-1 agonists but also by sigma-2 receptor agonists. 
In most behavioral tests, sigma-1 receptor agonists do not facilitate and sigma-1 
receptor antagonists do not impede the learning of healthy control animals. 
Downregulation of sigma-1 receptor expression using an in vivo antisense approach 
also does not affect the learning ability of healthy mice submitted to a passive avoidance test (60), (61). However, sigma-1 receptor agonists improve the performance of 
pharmacologically or pathologically lesioned animals in standard learning tests, and 
this improvement in lesioned rodents can be blocked by sigma-1 receptor antagonists. 
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2Table 1. Animal models in which sigma-1 agonists have shown anti-amnesic properties
Amnesia model Species σ1 agonists σ1 antagonists Other drugs used Behavioral tests Reference
Cholinergic deficit
Scopolamine Rat Igmesine, (+)-3-PPP, DTG None Piracetam Passive avoidance (151)
Scopolamine Mouse (+)-SKF 10,047, (±)-pentazocine None Ritanserin, mian-serin, 
tacrine, physostigmine
Passive avoidance (54)
Scopolamine, Ibotenic  
acid forebrain lesion
Rat SA4503 Haloperidol,  NE-100 None Passive avoidance (152)
Scopolamine Mouse (+)-SKF 10,047 Haloperidol, NE-100 (-)SKF 10,047,  
physostigmine
Passive avoidance (56)
Ibotenic acid forebrain lesion Rat SA4503 none None Morris water maze (153)
Scopolamine Mouse DHEA-S,  PREG-S Progesterone NE-100 None Y-maze, water maze (154)
Scopolamine Mouse PRE084, SA4503 Antisense mismatch antisense Y-maze, passive avoidance (155)
Scopolamine Rat OPC-14523 NE-100 None Morris water maze (156)
Nucleus basalis lesion Rat Fluoxetine None None Active avoidance (157)
Scopolamine Mouse (+)-pentazocine, (+)-SKF 10,047 antisense, NE-100 (-)pentazocine,  
U-50,488H
Y-maze (158) (159) 
(160)
Scopolamine Mouse ANAVEX1-41 antisense, BD1047 None Y-maze, passive avoidance, water 
 maze, forced swimming test
(161)
Scopolamine Mouse Dimemorfan Haloperidol None Passive avoidance Water maze (162)
192IgG-saporin induced 
lesions, Atropine sulfate
Rat (±)-PPCC BD1047 None Morris water maze (163)
L-NAME 7-nitroindazole Mouse (+)-SKF 10,047(+)-pentazocine NE-100 None Y-maze (164)
Amyloid-induced neurodegeneration




None Y-maze, passive avoidance (165)
ß-amyloid(25-35) peptide Mouse Donepezil, PRE084 BD1047 Tacrine, rivastigmine, 
galantamine
Y-maze, passive avoidance (166)
ß-amyloid(25-35) peptide Mouse ANAVEX1-41 BD1047 Scopolamine Y-maze, passive avoidance,  
radial arm maze
(75)
ß-amyloid(25-35) peptide Mouse Dimemorfan Haloperidol None Passive avoidance Water maze (167)
Aging-related memory loss
Senescence-accelerated mouse Mouse Igmesine, PRE084 BMY14802 JO1783 Y-maze, water maze, passive  
avoidance, open field
(168)
Normal aging Rat PRE084 none None Water maze (169)
Normal aging Rat OPC-14523 NE-100 None Morris water maze (170)
Normal aging Mouse PRE084 none None Morris water maze (171)
Hypoxia-induced neurodegeneration
Repeated CO exposure Mouse (+)-SKF 10,047, DTG BMY14802 None Y-maze, passive avoidance (172)
Repeated CO exposure Mouse PRE084, DTG, BD1008 NE-100, haloperidol None Passive avoidance (173)
Repeated CO exposure Mouse DHEA Pregnelone, NE-100 None Y-maze, passive avoidance (174)
Repeated CO exposure Mouse Donepezil, igmesine BD1047 Tacrine, rivastigmine, 
galantamine
Y-maze, passive avoidance (175)
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Table 1. Animal models in which sigma-1 agonists have shown anti-amnesic properties
Amnesia model Species σ1 agonists σ1 antagonists Other drugs used Behavioral tests Reference
Cholinergic deficit
Scopolamine Rat Igmesine, (+)-3-PPP, DTG None Piracetam Passive avoidance (151)
Scopolamine Mouse (+)-SKF 10,047, (±)-pentazocine None Ritanserin, mian-serin, 
tacrine, physostigmine
Passive avoidance (54)
Scopolamine, Ibotenic  
acid forebrain lesion
Rat SA4503 Haloperidol,  NE-100 None Passive avoidance (152)
Scopolamine Mouse (+)-SKF 10,047 Haloperidol, NE-100 (-)SKF 10,047,  
physostigmine
Passive avoidance (56)
Ibotenic acid forebrain lesion Rat SA4503 none None Morris water maze (153)
Scopolamine Mouse DHEA-S,  PREG-S Progesterone NE-100 None Y-maze, water maze (154)
Scopolamine Mouse PRE084, SA4503 Antisense mismatch antisense Y-maze, passive avoidance (155)
Scopolamine Rat OPC-14523 NE-100 None Morris water maze (156)
Nucleus basalis lesion Rat Fluoxetine None None Active avoidance (157)
Scopolamine Mouse (+)-pentazocine, (+)-SKF 10,047 antisense, NE-100 (-)pentazocine,  
U-50,488H
Y-maze (158) (159) 
(160)
Scopolamine Mouse ANAVEX1-41 antisense, BD1047 None Y-maze, passive avoidance, water 
 maze, forced swimming test
(161)
Scopolamine Mouse Dimemorfan Haloperidol None Passive avoidance Water maze (162)
192IgG-saporin induced 
lesions, Atropine sulfate
Rat (±)-PPCC BD1047 None Morris water maze (163)
L-NAME 7-nitroindazole Mouse (+)-SKF 10,047(+)-pentazocine NE-100 None Y-maze (164)
Amyloid-induced neurodegeneration




None Y-maze, passive avoidance (165)
ß-amyloid(25-35) peptide Mouse Donepezil, PRE084 BD1047 Tacrine, rivastigmine, 
galantamine
Y-maze, passive avoidance (166)
ß-amyloid(25-35) peptide Mouse ANAVEX1-41 BD1047 Scopolamine Y-maze, passive avoidance,  
radial arm maze
(75)
ß-amyloid(25-35) peptide Mouse Dimemorfan Haloperidol None Passive avoidance Water maze (167)
Aging-related memory loss
Senescence-accelerated mouse Mouse Igmesine, PRE084 BMY14802 JO1783 Y-maze, water maze, passive  
avoidance, open field
(168)
Normal aging Rat PRE084 none None Water maze (169)
Normal aging Rat OPC-14523 NE-100 None Morris water maze (170)
Normal aging Mouse PRE084 none None Morris water maze (171)
Hypoxia-induced neurodegeneration
Repeated CO exposure Mouse (+)-SKF 10,047, DTG BMY14802 None Y-maze, passive avoidance (172)
Repeated CO exposure Mouse PRE084, DTG, BD1008 NE-100, haloperidol None Passive avoidance (173)
Repeated CO exposure Mouse DHEA Pregnelone, NE-100 None Y-maze, passive avoidance (174)
Repeated CO exposure Mouse Donepezil, igmesine BD1047 Tacrine, rivastigmine, 
galantamine
Y-maze, passive avoidance (175)
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2Table 1. Continued
Amnesia model Species σ1 agonists σ1 antagonists Other drugs used Behavioral tests Reference
Toxin-induced neurodegeneration (aspecific)
Trimethyltin Rat Igmesine none None passive avoidance,  
radial arm maze
(176)
Trimethyltin Mouse PRE084, DTG, BD1008 NE-100, haloperidol None Passive avoidance (177)
Prenatal stress
Prenatal restraint Rat Igmesine BD1063 None Y-maze, T-maze, water  
maze, passive avoidance
(178)




Dizocilpine Mouse (+)-SKF 10,047, (+)-pentazocine, DTG BMY14802, NE-100 (-)SKF 10,047,  
(-)pentazocine
Y-maze, passive avoidance,  
elevated plus maze
(180)
Dizocilpine Rat (+)-SKF 10,047 (-)SKF 10,047 Three-panel runway task (181)
Dizocilpine Mouse DHEA-S BMY14802, haloperidol Y-maze, passive avoidance (182)
Dizocilpine Mouse SA4503 Haloperidol, progesterone L-NAME Y-maze, passive avoidance (183)
Dizocilpine Rat (+)-SKF 10,047, SA4503 NE-100 None Radial arm maze (184)
Dizocilpine Rat SA4503, DHEA-S, PREG-S Progesterone, NE-100 None Radial arm maze (185)
Dizocilpine Mouse PRE084, SA4503 Antisense Mismatch antisense Y-maze, passive avoidance (186)
Dizocilpine Mouse PRE084, DHEA-S, PREG-S Antisense Mismatch antisense Y-maze, passive avoidance (187)
Phencyclidine, dizocilpine Mouse SA4503,  (+)-pentazocine, (+)-SKF 10,047 NE-100 D-cycloserine, L-NAME One-trial water-finding task (188)
Dizocilpine Mouse Donepezil, igmesine Antisense, BD1047 Rivastigmine, tacrine Y-maze, passive avoidance (189)
Phencyclidine Mouse Fluvoxamine, SA4503, DHEA-S NE-100 Paroxetine Novel object recognition task (190)
Phencyclidine Mouse Donepezil NE-100 Physostigmine Novel object recognition task (191)
Serotonergic deficit
p-chloroamphe-tamine Mouse (+)-SKF 10,047, (±)-pentazocine none Ritanserin, mianserin, 
tacrine, physostigmine
Passive avoidance (54)
p-chloroamphe- tamine Mouse (+)-SKF 10,047, DTG, (+)-3-PPP none (-)SKF 10,047, 
hemicholinium-3
Passive avoidance (53)
Ca2+ channel  deficit




CDEP Mouse (+)-SKF 10,047, DTG, (+)-3-PPP none None Passive avoidance (192)
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Table 1. Continued
Amnesia model Species σ1 agonists σ1 antagonists Other drugs used Behavioral tests Reference
Toxin-induced neurodegeneration (aspecific)
Trimethyltin Rat Igmesine none None passive avoidance,  
radial arm maze
(176)
Trimethyltin Mouse PRE084, DTG, BD1008 NE-100, haloperidol None Passive avoidance (177)
Prenatal stress
Prenatal restraint Rat Igmesine BD1063 None Y-maze, T-maze, water  
maze, passive avoidance
(178)




Dizocilpine Mouse (+)-SKF 10,047, (+)-pentazocine, DTG BMY14802, NE-100 (-)SKF 10,047,  
(-)pentazocine
Y-maze, passive avoidance,  
elevated plus maze
(180)
Dizocilpine Rat (+)-SKF 10,047 (-)SKF 10,047 Three-panel runway task (181)
Dizocilpine Mouse DHEA-S BMY14802, haloperidol Y-maze, passive avoidance (182)
Dizocilpine Mouse SA4503 Haloperidol, progesterone L-NAME Y-maze, passive avoidance (183)
Dizocilpine Rat (+)-SKF 10,047, SA4503 NE-100 None Radial arm maze (184)
Dizocilpine Rat SA4503, DHEA-S, PREG-S Progesterone, NE-100 None Radial arm maze (185)
Dizocilpine Mouse PRE084, SA4503 Antisense Mismatch antisense Y-maze, passive avoidance (186)
Dizocilpine Mouse PRE084, DHEA-S, PREG-S Antisense Mismatch antisense Y-maze, passive avoidance (187)
Phencyclidine, dizocilpine Mouse SA4503,  (+)-pentazocine, (+)-SKF 10,047 NE-100 D-cycloserine, L-NAME One-trial water-finding task (188)
Dizocilpine Mouse Donepezil, igmesine Antisense, BD1047 Rivastigmine, tacrine Y-maze, passive avoidance (189)
Phencyclidine Mouse Fluvoxamine, SA4503, DHEA-S NE-100 Paroxetine Novel object recognition task (190)
Phencyclidine Mouse Donepezil NE-100 Physostigmine Novel object recognition task (191)
Serotonergic deficit
p-chloroamphe-tamine Mouse (+)-SKF 10,047, (±)-pentazocine none Ritanserin, mianserin, 
tacrine, physostigmine
Passive avoidance (54)
p-chloroamphe- tamine Mouse (+)-SKF 10,047, DTG, (+)-3-PPP none (-)SKF 10,047, 
hemicholinium-3
Passive avoidance (53)
Ca2+ channel  deficit




CDEP Mouse (+)-SKF 10,047, DTG, (+)-3-PPP none None Passive avoidance (192)
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2Neuroactive steroids (such as DHEA-S or pregnenolone sulfate) have similar effects as non-steroid sigma-1 receptor agonists, whereas progesterone behaves as a sigma-1 receptor antagonist. These observations suggest that sigma-1 receptors are not directly involved in learning or memory, but sigma-1 receptor agonists can modulate neural processes underlying cognition, particularly under pathological conditions.  However, in some publications pro-mnesic effects of sigma-1 receptor agonists have been reported.  For example, the neurosteroids DHEA-S and PREG-S, when 
given either pre- or post-training, were found to facilitate retention of a modified learning task in mice in a dose-dependent manner with a bell-shaped dose-response curve. This action of the neurosteroids appears to be dependent on their interaction with sigma-1 receptors, since it can be blocked by concurrent administration of the sigma antagonist haloperidol (62). Long-term potentiation (LTP) in rat hippocampus, a process thought to be crucial for learning and memory, is facilitated after chronic (7 d) administration of the neurosteroid DHEA-S. This potentiation appears to be based on alterations in postsynaptic neurons since no changes were observed in presynaptic glutamate release. DHEA-S appears to act through sigma-1 receptors, since the potentiating effect is absent when sigma-1 receptor antagonists (NE-100, haloperidol) are co-administered with the neurosteroid (63). Another neurosteroid with sigma-1 receptor agonist action, PREG-S, has also been reported to facilitate LTP in the rodent hippocampus by a mechanism involving sigma-1 receptors and L-type calcium channels (64). The non-sulfated forms of the neurosteroids which lack the sigma-1 receptor agonist action (DHEA and PREG) do not potentiate LTP (65), (64). Paired-pulse facilitation in hippocampal neurons from adult rats, a short-term increase of the postsynaptic potential, is also potentiated by PREG-S and this potentiation is abolished after co-administration of sigma-1 receptor antagonists (66).  
IMPROVEMENT OF COGNITIVE FUNCTION  
IN HUMANSFluvoxamine has been reported to be effective in improving cognitive impairments in an animal model of schizophrenia, in contrast to paroxetine (67). 
Interestingly, fluvoxamine but not paroxetine was also found to improve the lack of concentration, poor memory, slowness of mind, and poor executive function in a patient with schizophrenia (68). The affinity of fluvoxamine for sigma-1 receptors is more than 50 times higher than that of paroxetine, although both compounds are potent selective serotonin reuptake inhibitors (SSRIs) (69). High occupancy (up to 60%) of sigma-1 receptors in the human brain was observed with 11C-
SA4503 PET after a single oral dose of 200 mg fluvoxamine (70) (see Figure 4 for a similar occupancy study). These data suggest that sigma-1 receptor agonists 
including SSRIs with sigma-1 receptor agonist action, such as fluvoxamine, may be candidates for treating cognitive impairments in schizophrenia. 
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Compounds which combine acetylcholinesterase (AChE) inhibition with sigma-1 receptor agonism exist as well, e.g. donepezil. A recent paper reported that therapeutic 
doses of donepezil result in considerable sigma-1 receptor occupancy in human brain (71). Sigma-1 receptor agonists may have potential for treating AD since the 
compounds are not only capable of alleviating cognitive deficits in animal models of 
cognitive impairment (see above) but they can also provide neuroprotection against amyloid toxicity (see (72) for a review). Evidence for such neuroprotective activity 
has been provided both by in vitro experiments in cultured cortical neurons (73) and by in vivo studies in rodents (74), (75). Recently, it was found that sigma-1 receptor 
agonists can powerfully suppress microglial activation (76). Such compounds may 
therefore attenuate the inflammatory component in neurodegenerative diseases. 
More applications of sigma-1 receptor agonists, e.g. in the treatment of depression, anxiety, psychosis, substance abuse, stroke and neuropathic pain 
are discussed in several recent reviews (77), (78), (79), (80), (29), (81). Companies 
involved in the development of drugs for such indications include M’s Science, 
AGY Therapeutics, Otsuka American Pharmaceutical, and Sanofi-Aventis (78)
MODULATION OF GLUTAMATE RELEASE  
BY SIGMA-1 AGONISTS
Besides the well-known deficits of acetylcholine, the neurotransmitter glutamate 
can be reduced in AD. Both neurotransmitters are supposed to play vital roles in memory (82). It is thus of interest that sigma ligands are capable of modulating 
glutamate release in various areas of the brain. 
Figure 4. PET scans of the brain of a human volunteer, made with the sigma-1 receptor 
ligand 11C-SA4503, at baseline (left) and after oral administration of an antipsychotic 
drug, interval 3 h (middle) and 10 h (right), respectively. The binding of 11C-SA4503 was 
considerably reduced after occupancy of sigma-1 receptors by the antipsychotic drug. Data 
from our own group, not previously published.
43
2The neurosteroid PREGS (which is supposed to act as a sigma-1 receptor agonist) and the sigma-1 receptor agonist (+)-pentazocine, but not the (-)-enantiomers of PREGS and pentazocine, or the inactive steroid isopregnanolone enhance the spontaneous release of glutamate in cultured hippocampal neurons. The sigma receptor antagonists haloperidol and BD1063 and a membrane-permeable calcium chelator block this effect of PREGS. These results suggest that hippocampal glutamate release can be enhanced via activation of presynaptic sigma-1 receptors and an elevation of the levels of intracellular Ca2+ (83). Later 
studies by another research group confirmed that the spontaneous release of glutamate is enhanced by PREGS both in the hippocampus and in prelimbic cortex, but not in the striatum. The effect of PREGS in the prelimbic cortex appears to be mediated via alpha-1 adrenergic and sigma-1 receptors, whereas the effect in the hippocampus is dependent on sigma-1 receptors only. Intracellular calcium released from the endoplasmatic reticulum plays a key role in the enhancement of glutamate release (84). DHEA-S, another neurosteroid with sigma-1 receptor agonist action, also enhances the spontaneous release of glutamate in prelimbic cortex and hippocampus. The effect of this compound in the prelimbic cortex appears to be mediated via dopamine D1 and sigma-1 receptors, whereas that in the hippocampus occurs only via sigma-1 receptors (85).Brain-derived neurotrophic factor (BDNF)-induced glutamate release in cultured cortical neurons is potentiated by antidepressants with sigma-1 receptor 
agonist activity such as fluvoxamine and imipramine, and this potentiation is blocked by the sigma-1 receptor antagonist BD1047. Not only pharmacological activation but also overexpression of the sigma-1 receptor enhances BDNF-enhanced glutamate release. The sigma-1 receptor appears to play an important role in BDNF signaling leading to the release of glutamate, and the enhancement of glutamate release seems to occur via the  PLC-gamma/IP3/Ca2+ pathway (86).Thus, sigma ligands represent a strategy for modulating glutamatergic activity within the mammalian brain, and such modulation could be an additional mechanism underlying the anti-amnesic action of sigma-1 receptor agonists.
MODULATION OF THE NMDA RESPONSE  
BY SIGMA-1 AGONISTSNMDA receptors mediate the induction of LTP and long-term depression in various brain areas (i.e. long-lasting improvements and impairments of synaptic transmission) (87), (88), (89), (90). Such forms of synaptic plasticity are considered as important cellular mechanisms underlying learning and memory (91), (92), (93). Pharmacological inhibition of NMDA receptor function, by administration of NMDA antagonists either directly into the brain or by systemic administration of compounds which can cross the blood-brain barrier, results in impaired spatial learning and nonspatial passive avoidance learning in rodents (94), (95), (96), 
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(97). Knockout mice lacking the NMDA receptor 1 gene in CA1 pyramidal cells 
of the hippocampus exhibit impaired spatial learning but unimpaired nonspatial 
learning (98). Apparently, NMDA-dependent strengthening of CA1 synapses is 
essential for the acquisition and storage of spatial memory. 
In many studies, sigma-1 receptor agonists were shown to modulate 
responses induced by NMDA receptor activation in various brain areas such as 
the hippocampus and prefrontal cortex. Some responses are potentiated and 
others inhibited by sigma-1 receptor agonists. Sigma-1 receptor antagonists 
when administered alone are without any effect, but these compounds block the 
agonist-induced modulation. 
For example, the electrophysiological response of pyramidal neurons in the CA3 
region of the rat dorsal hippocampus to NMDA (excitatory activation) is potentiated 
by sigma-1 receptor agonists such as (+)pentazocine, DTG, BD737, igmesine, 
L687,384, or DHEA and therapeutic drugs with significant sigma-1 receptor agonist 
affinity (the SSRI sertraline and the monoamine oxidase inhibitor clorgyline), 
whereas this potentiation is reversed by sigma-1 receptor antagonists such as 
haloperidol, BMY14802, NE-100, progesterone and testosterone (99), (100), (101), 
(102), (103), (104), (105). The potentiation persists for at least 60 minutes and can 
be sustained by prolonged microiontophoretic application of a sigma-1 receptor 
agonist, indicating that sigma-1 receptors do not rapidly desensitize (99).
Steroid hormones with antagonist action such as progesterone and 
testosterone produce a tonic dampening of the function of sigma-1 receptors and, 
consequently, of NMDA-mediated responses. Pregnancy reduces sigma-1 receptor 
function in the brain, since a tenfold higher dose of sigma-1 receptor agonists 
is required to potentiate the NMDA-response of  pyramidal neurons in pregnant 
female rats than in non-pregnant control animals (106).
In an electrophysiological study in which animals were unilaterally lesioned 
by local injection of colchicine into the mossy fiber system (an afferent system 
to CA3 pyramidal neurons), the potentiating effect of (+)-pentazocine on the 
NMDA-response was found to persist on the lesioned side, but the potentiating 
effects of DTG and igmesine were abolished after lesioning (107). These data were 
interpreted as suggesting that the test drugs were acting on two different subtypes 
of sigma receptors, and that the receptors for DTG and igmesine are located on 
the mossy fiber terminals, in contrast to the receptors for (+)-pentazocine (107). 
In a later study, the effect of the sigma-2 subtype-selective ligand siramesine was 
tested on the neuronal response to NMDA in the CA3 region of the rat dorsal 
hippocampus. Siramesine was found to potentiate the NMDA response dose-
dependently with a bell-shaped curve, but the effect of siramesine could - in 
contrast to the effect of sigma-1 receptor agonists - not be reversed by NE-100, 
haloperidol or progesterone (108). Thus, not only sigma-1 but also sigma-2 
receptors appear to be involved in modulation of the NMDA response.
Bell-shaped dose-response curves are a common finding in studies regarding 
the effect of sigma-1 receptor agonists. At low doses the NMDA response is 
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2potentiated but at higher dose the potentiation is reversed (99), (109), (110), (103). 
For example, the sigma-1 receptor agonist SR 31742A increases NMDA-induced 
inward currents of pyramidal cells in slices of rat medial prefrontal cortex at 
doses ranging from 10 to 100 nM (EC
50
 23 nM), but at doses greater than 100 
nM an inhibition is observed (111). The potentiaton of NMDA-receptor mediated 
neurotransmission by SR 31742A may account for the antipsychotic and cognition-
enhancing properties of the drug, whereas the inhibition of NMDA responses at 
higher drug concentrations may account for its neuroprotective effect (112).
Recently, a molecular mechanism has been proposed which may explain how 
sigma-1 receptor ligands increase the NMDA response. Calcium ions entering the cells 
through NMDA-receptor-related channels normally activate a potassium current via 
small-conductance calcium-activated K+ channels (SK channels). This current shunts 
the NMDA receptor responses. Sigma-1 subtype-selective receptor agonists prevent 
SK channel opening, and consequently increase the NMDA receptor response (113).
MODULATION OF CALCIUM HOMEOSTASIS
The intracellular localization of sigma-1 receptors (mainly in endoplasmatic 
reticulum, but also in nuclear and plasma membranes and on mitochondria (114), 
(115), (116), (117), (118)) suggests that these binding sites could be involved in the 
regulation of calcium mobilization.
Indeed, sigma-1 receptor activation has been shown to affect calcium 
homeostasis. Sigma-1 receptor agonists increased contractility, beating rate and 
calcium influx in cultured cardiac myocytes from neonatal rats (119). Intracellular 
levels of inositol triphosphate in these cells were increased as well (120). In NG108 
(neuroblastoma-glioma) cells, various sigma-1 receptor agonists enhanced the 
bradykinin-induced increases in cytosolic free calcium with bell-shaped dose-
response curves whereas this effect could be blocked by a sigma-1 receptor 
antisense oligonucleotide, suggesting that sigma-1 receptor activation facilitates 
IP
3
-receptor-mediated Ca2+ signaling (121). In SH-SY5Y (neuroblastoma) cells, 
the sigma-1 receptor agonist (+)-pentazocine and various neurosteroids also 
potentiated the bradykinin-induced Ca2+ response, and this potentiation was 
blocked by the sigma receptor antagonists haloperidol and progesterone (122). By 
expression of either complete sigma-1 receptors or the N- or C-terminal segment of 
the sigma-1 receptor protein in MCF-7 breast cancer cells (which normally express 
few sigma-1 receptors), proof was obtained that sigma-1 receptor overexpression 
results in an enhancement of bradykinin-, vasopressin- or ATP-induced calcium 
release, and that the C-terminal segment of the sigma-1 receptor is involved in the 
interaction with the inositol triphosphate receptor-ankyrin-B 220 complex (123).
Experiments in adult guinea pig isolated brainstem preparations have indicated 
that sigma-1 receptor activation leads to activation of phospholipase C and the 
beta-1 and beta-2 isoforms of protein kinase C (124). In isolated rat hippocampal 
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neurons, receptor activation leads to a potentiation of NMDA-receptor-mediated 
increases of free intracellular calcium (125). However, in rat frontal cortical 
neurons, sigma receptor ligands were found to reduce the NMDA-induced Ca2+ 
influx. Sigma-1-subtype-selective compounds (igmesine, (+)-pentazocine) 
particularly affected the sustained phase of the Ca2+ response to NMDA, whereas 
non-subtype-selective compounds (DTG, haloperidol) reduced the initial and 
sustained phases to the same degree. The inhibition of the sustained phase was 
directly related to the affinity of the ligands to sigma-1 receptors. Thus, in frontal 
cortical neurons, sigma-1 receptors appear to facilitate the desensitization of the Ca2+ response to NMDA (126). Attenuation of NMDA-induced calcium responses 
by sigma ligands in frontal cortical neurons was also observed in a later study, 
and  that study confirmed that sigma ligands shifted the NMDA response from a 
sustained to a biphasic or transient event (127).
In an interesting study on the sigma-1 receptor agonist igmesine, the effect 
of intracerebroventricularly administered modulators of calcium influx and 
mobilization was examined on the reduction of immobilization time caused 
by igmesine in the forced swimming test. Using chelators of extracellular 
and intracellular calcium, L- and N-type voltage-dependent calcium channel 
antagonists and agonists, evidence was obtained that the antidepressant effect 
of igmesine is dependent not only on rapid Ca2+ influx (like that of classical 
antidepressants), but also on intracellular Ca2+ mobilization (128). 
Antagonists of voltage-dependent calcium channels such as nimodipine impair 
the cognitive performance of rodents in various learning tests. Such impairments 
could be attenuated by pre-administration of the sigma-1 receptor agonists PRE-
084, and this attenuation could be completely prevented by co-administration 
of the sigma-1 receptor antagonist BMY-14802. Thus, calcium fluxes are implied 
in memory processes and an impairment of calcium influx through voltage-
dependent calcium channels can, at least partially, be overcome by administration 
of a sigma-1 receptor agonist (129). Potentiation or attenuation of calcium signaling 
via sigma-1 receptors (both Ca2+ entry at the plasma membrane level via channels and Ca2+ mobilization from intracellular stores) may explain why selective sigma-1 
receptor agonists can modulate a wide variety of neuronal responses, and be the 
key mechanism by which sigma-1 receptors affect learning and memory (130).
INVOLVEMENT OF SIGMA-1 RECEPTORS  
IN NEURONAL DIFFERENTIATION  
AND NEUROPLASTICITY
Sigma-1 receptors are expressed not only in neurons but also in astrocytes and 
oligodendrocytes within the brain (131), (132). Overexpression of sigma-1 receptors 
potentiates nerve growth factor (NGF)-induced neurite outgrowth in PC-12 cells, and 
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2this effect can be blocked by sigma-1 receptor antisense (133). Sigma-1 receptors are 
strongly upregulated in the corpus callosum of developing brains, particularly in the 
phase of active myelination (134). A high expression of these binding sites is observed 
in oligodendrocytes (135) and Schwann cells (136), suggesting involvement of the 
sigma-1 receptor in myelination. Knockdown of these receptors by siRNA results 
in complete inhibition of the differentiation and myelination of oligodendrocyte 
progenitor cells (137) and prevention of the formation of mature dendritic spines 
in hippocampal primary neurons (26). Eliprodil, a neuroprotective drug with a high 
affinity agonist action at sigma receptors, strongly promotes myelination in neuron-
oligodendrocyte cocultures. These data suggest that upregulation of sigma-1 
receptors is an important prerequisite for neuronal differentiation, and that sigma-1 
receptor agonists like eloprodil may be of therapeutic interest in demyelinating 
diseases such as multiple sclerosis (138).
Overexpression of sigma-1 receptors promotes lipid reconstitution in 
the plasma membrane and potentiates raft-residing neurotrophic factors 
receptors and signal transduction (NGF, EGF, BNDF) (139), (140), (141), (142). 
These neurotrophic factor signaling pathways may therefore be involved in 
the differentiation-promoting effects of sigma-1 receptors. When PC-12 cells 
are treated with NGF and verbenachalcone, a differentiation enhancer, the 
sigma-1 receptor belongs to the 10 (out of 10,000) genes showing the strongest 
upregulation (143). Since a very high expression of sigma-1 receptors has been 
noticed in the ventricular zone of young rat brains, where active proliferation 
and differentiation of cells occurs (144), sigma-1 receptors may not only play an 
important role in neuroplasticity but may also be involved in neurogenesis.  An 
involvement of sigma-1 receptors in neurogenesis is suggested by the observation 
that continuous administration of the sigma-1 agonist SA4503 dose-dependently 
enhances the number of bromodeoxyuridine-positive cells in the subgranular 
zone of the adult rat hippocampus (by 48% at 3 mg/kg/d and by 94% at 10 mg/
kg/d, respectively, after a treatment period of 3 days), indicating an increased 
cellular proliferation. Since SA4503 causes parallel increases of hippocampal 
5-HT neurotransmission and cell proliferation, the neurotransmitter serotonin 
may play a central role in the proliferation process (145).
Not only sigma-1 receptor overexpression, but also drug-induced sigma-1 
receptor activation results in potentiation of NGF-induced neurite outgrowth. 
Donepezil, a combined sigma-1 receptor ligand and AChE inhibitor (IC
50
 values 
14.6 nM and 21.5 nM, respectively (146)), potentiates NGF-induced neurite 
outgrowth in PC12 cells, and this effect of donepezil can be blocked by the sigma-1 
receptor antagonist NE-100 or the inositol 1,4.5-triphosphate (IP
3
)-receptor 
antagonist xestospongin C (147), but is not affected by cholinoceptor antagonists 
(mecamylamine, scopolamine) or cholinomimetic drugs (nicotine, carbachol) 
(148). Physostigmine, an AChE inhibitor without sigma-1 receptor affinity, does 
not alter NGF-induced neurite outgrowth (149). The SSRI fluvoxamine (but not 
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the SSRIs sertraline or paroxetine) and the sigma-1 receptor agonists SA4503, 
PPBP and DHEA-sulfate likewise potentiate neurite outgrowth in PC12 cells in a 
concentration-dependent manner, and the effect of these drugs can also be blocked 
by NE-100 or xestospongin C (150). Since sertraline and fluvoxamine have similar 
affinities to sigma-1 receptors (69) but only fluvoxamine promotes outgrowth, these 
data may indicate that sertraline is a sigma-1 receptor antagonist and fluvoxamine 
a sigma-1 receptor agonist (150).  Specific inhibitors of phospholipase C (PLC), 
phosphatidyl inositol 3-kinase (PI3K), p38 mitogen-activated protein kinase 
(p38MAPK), c-Jun terminal kinase (JNK), and the Ras/Raf/mitogen-activated 
protein kinase signaling pathways block the potentiation of NGF-induced neurite 
outgrowth as well (150). Apparently, both sigma-1 receptors and IP
3
-receptors are 
involved in the potentiation of neurite outgrowth by the test drugs, besides the 
PLC, PI3K, p38MAPK, JNK and the Ras/Raf/MAPk  signaling pathways.
CONCLUSION
Because of the neuromodulatory role of sigma-1 receptors, ligands for these 
binding sites can affect a large variety of cerebral processes. Modification of calcium 
transients (both by affecting calcium release from intracellular stores and influx 
of extracellular calcium) and modulation of potassium channel activity via direct 
protein-protein interaction appear to be key processes underlying the action of 
sigma-1 receptor ligands. Probably via these mechanisms, several neurotransmitter 
systems are modulated, particularly the cholinergic and glutamatergic (NMDA-
receptor) pathways. The modulatory role of sigma-1 receptors explains why 
sigma-1 receptor ligands are usually devoid of an effect under control conditions 
but have striking effects when the normal homeostasis of the organism has been 
disturbed, e.g. by disease or by a pharmacological challenge. Data from preclinical 
studies in a large variety of animal models suggests that sigma-1 receptor agonists 
are promising compounds for the treatment of cognitive dysfunction.
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